≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Melanocytic naevi of ear and external auricular canal

DOID EFO Endpoint Browser PheWeb

CD2_BENIGN_MELANOCYTIC_EAR

cutaneous melanoma: A primary melanoma arising from atypical melanocytes in the skin. Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi. Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D22.2&
  • Hospital discharge: ICD-9 — 2162A
  • Cause of death: ICD-10 — D22.2&
  • Cause of death: ICD-9 — 2162A

2 out of 7 registries used, show all original rules.

226

4. Check minimum number of events

None

226

5. Include endpoints

None

226

6. Filter based on genotype QC (FinnGen only)

223

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D22
Name in latin
Naevus melanocyticus (cutis) auriculae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1330 810 508
Only index persons 1251 778 473
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.01
Only index persons 0.02 0.03 0.02
Median age at first event (years)
Whole population 49.38 45.07 56.22
Only index persons 48.91 44.97 55.38

-FinnGen-

Key figures

All Female Male
Number of individuals 223 150 73
Unadjusted period prevalence (%) 0.05 0.05 0.03
Median age at first event (years) 51.90 45.93 64.16

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
226
Matched controls
2260
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D22.2
ICD-10 Finland
Melanocytic naevi of ear and external auricular canal
4503599627370496.0
302.8
218
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
11.8
62.1
77
95
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
7.4
35.0
60
105
DAB00
NOMESCO Finland
Excision of lesion of auricle
47.9
27.6
33
8
D22.5
ICD-10 Finland
Melanocytic naevi of trunk
6.8
24.2
42
73
D23.2
ICD-10 Finland
Benign neoplasm: Skin of ear and external auricular canal
32.9
16.4
21
7
R23.8
ICD-10 Finland
Other and unspecified skin changes
3.2
14.8
80
329
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
5.3
14.8
32
68
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
4.9
14.4
35
82
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
12.1
11.3
20
18
DAB10
NOMESCO Finland
Partial excision of auricle
45.7
11.0
13
*
S82
ICPC
Naevus/mole
3.0
10.4
57
231
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
10.8
9.7
18
18
D22.9
ICD-10 Finland
Melanocytic naevi, unspecified
4.2
9.3
26
68
D22.3
ICD-10 Finland
Melanocytic naevi of other and unspecified parts of face
8.2
8.8
19
25
XQ848
NOMESCO Finland
Dermatological photography
9.1
8.5
17
20
2162A
ICD-9 Finland
Benign neoplasm of skin, Ear and external auditory canal[KORVAN IHON BEN KASVAIN,NAEVUS PIGMENTOSUS]
+∞
8.4
8
*
XQ845
NOMESCO Finland
Dermatoscopy
10.6
8.2
15
15
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
3.6
7.7
27
83
L82
ICD-10 Finland
Seborrhoeic keratosis
2.5
7.6
56
262
D22
ICD-10 Finland
Melanocytic naevi
3.7
6.8
22
64
D22.4
ICD-10 Finland
Melanocytic naevi of scalp and neck
10.5
6.6
12
12
TQW99
NOMESCO Finland
Other minor procedure on skin
3.7
6.5
21
61
TDA10
NOMESCO Finland
Needle biopsy of auricle or external auditory canal
27.5
6.3
8
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
3.3
6.1
23
74

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
9.4e-01
1.6e+00
2.5e+00
1.0e+50
2.7e+00
1.9e+00
1.0e+00
cases:19.37%
controls:8.62%
cases:13.96%
controls:3.20%
cases:6.76%
controls:0.59%
cases:33.78%
controls:0.00%
cases:6.82%
controls:0.50%
cases:18.14%
controls:3.20%
cases:21.39%
controls:8.87%
43
191
179
2026
31
71
191
2146
15
13
207
2204
75
0
147
2217
15
11
205
2200
39
69
176
2086
40
162
147
1664
Otolaryngology
4 [38004449]
4.8e-01
1.1e+00
2.9e+00
—
4.2e+00
1.4e+00
6.7e-01
cases:15.32%
controls:10.10%
cases:10.81%
controls:3.79%
cases:9.01%
controls:0.54%
—
—
cases:17.27%
controls:0.32%
cases:13.49%
controls:3.62%
cases:19.25%
controls:10.90%
34
224
188
1993
24
84
198
2133
20
12
202
2205
—
38
7
182
2204
29
78
186
2077
36
199
151
1627
Outpatient Visit
OP [9202]
3.3e-01
5.4e-01
6.2e-01
5.8e+00
1.5e+00
7.3e-01
6.3e-01
cases:79.73%
controls:73.88%
cases:63.96%
controls:50.74%
cases:19.82%
controls:11.77%
cases:63.96%
controls:0.54%
cases:36.36%
controls:11.08%
cases:67.44%
controls:49.93%
cases:85.56%
controls:75.90%
177
1638
45
579
142
1125
80
1092
44
261
178
1956
142
12
80
2205
80
245
140
1966
145
1076
70
1079
160
1386
27
440
Melanocytic naevi of trunk
D22.5 [45542688]
2.0e+00
2.5e+00
—
1.0e+50
1.0e+50
2.3e+00
1.8e+00
cases:2.70%
controls:0.36%
cases:2.70%
controls:0.23%
—
—
cases:2.70%
controls:0.00%
cases:2.27%
controls:0.00%
cases:2.79%
controls:0.28%
cases:5.35%
controls:0.93%
6
8
216
2209
6
5
216
2212
—
6
0
216
2217
5
0
215
2211
6
6
209
2149
10
17
177
1809
Tissue Pathology biopsy report
66121-5 [40768804]
5.4e-01
1.7e+00
2.8e+00
1.0e+50
2.3e+00
9.6e-01
8.8e-01
cases:13.96%
controls:8.66%
cases:13.51%
controls:2.84%
cases:5.41%
controls:0.36%
cases:18.92%
controls:0.00%
cases:3.64%
controls:0.36%
cases:6.98%
controls:2.78%
cases:20.86%
controls:9.86%
31
192
191
2025
30
63
192
2154
12
8
210
2209
42
0
180
2217
8
8
212
2203
15
60
200
2095
39
180
148
1646
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
1.8e+00
2.9e+00
—
1.0e+50
—
—
2.0e+00
cases:6.76%
controls:1.17%
cases:4.50%
controls:0.27%
—
—
cases:10.36%
controls:0.00%
—
—
—
—
cases:7.49%
controls:1.04%
15
26
207
2191
10
6
212
2211
—
23
0
199
2217
—
—
14
19
173
1807
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
2.3e+00
—
—
—
—
2.3e+00
1.9e+00
cases:3.60%
controls:0.36%
—
—
—
—
—
—
—
—
cases:3.26%
controls:0.32%
cases:4.28%
controls:0.66%
8
8
214
2209
—
—
—
—
7
7
208
2148
8
12
179
1814
Removal of sutures
SPAT1153 [2001700254]
5.6e-01
1.1e+00
—
—
3.5e+00
1.8e+00
6.6e-01
cases:6.76%
controls:3.97%
cases:5.86%
controls:2.03%
—
—
—
—
cases:6.82%
controls:0.23%
cases:7.44%
controls:1.30%
cases:9.09%
controls:4.93%
15
88
207
2129
13
45
209
2172
—
—
15
5
205
2206
16
28
199
2127
17
90
170
1736
Other and unspecified skin changes
R23.8 [45573020]
7.6e-01
2.6e+00
—
—
—
1.6e+00
1.2e+00
cases:4.95%
controls:2.39%
cases:8.11%
controls:0.68%
—
—
—
—
—
—
cases:4.19%
controls:0.88%
cases:11.23%
controls:3.72%
11
53
211
2164
18
15
204
2202
—
—
—
9
19
206
2136
21
68
166
1758
Laceration/cut
S18 [2002000983]
3.7e-01
1.3e+00
—
—
2.9e+00
1.1e+00
3.1e-01
cases:9.46%
controls:6.72%
cases:9.01%
controls:2.75%
—
—
—
—
cases:9.09%
controls:0.54%
cases:8.37%
controls:2.83%
cases:13.90%
controls:10.62%
21
149
201
2068
20
61
202
2156
—
—
20
12
200
2199
18
61
197
2094
26
194
161
1632
Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]
2.1e+00
3.0e+00
1.0e+50
—
—
—
2.2e+00
cases:2.25%
controls:0.27%
cases:4.95%
controls:0.27%
cases:4.05%
controls:0.00%
—
—
—
—
—
—
cases:3.21%
controls:0.38%
5
6
217
2211
11
6
211
2211
9
0
213
2217
—
—
—
6
7
181
1819
Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]
2.3e+00
2.3e+00
—
—
—
—
1.5e+00
cases:4.95%
controls:0.50%
cases:2.70%
controls:0.27%
—
—
—
—
—
—
—
—
cases:3.74%
controls:0.82%
11
11
211
2206
6
6
216
2211
—
—
—
—
7
15
180
1811
Laboratory Visit
OMOP4822461 [32036]
2.7e-02
1.8e-01
8.1e-01
3.4e+00
6.3e-01
1.2e-01
9.8e-02
cases:41.44%
controls:40.78%
cases:42.34%
controls:38.11%
cases:23.42%
controls:11.95%
cases:21.62%
controls:0.90%
cases:18.18%
controls:10.58%
cases:43.26%
controls:40.42%
cases:62.57%
controls:60.24%
92
904
130
1313
94
845
128
1372
52
265
170
1952
48
20
174
2197
40
234
180
1977
93
871
122
1284
117
1100
70
726
Case Management Agency
251B00000X [38004193]
2.4e-01
2.9e-01
2.9e-01
3.2e+00
7.2e-01
8.3e-02
-2.8e-02
cases:69.37%
controls:64.01%
cases:64.86%
controls:58.10%
cases:31.53%
controls:25.62%
cases:29.28%
controls:1.62%
cases:41.36%
controls:25.64%
cases:62.79%
controls:60.84%
cases:77.01%
controls:77.49%
154
1419
68
798
144
1288
78
929
70
568
152
1649
65
36
157
2181
91
567
129
1644
135
1311
80
844
144
1415
43
411
Actinic keratosis
L57.0 [45591640]
1.0e+00
1.4e+00
—
1.0e+50
—
1.9e+00
1.8e+00
cases:4.50%
controls:1.67%
cases:3.60%
controls:0.90%
—
—
cases:3.15%
controls:0.00%
—
—
cases:4.65%
controls:0.74%
cases:8.02%
controls:1.42%
10
37
212
2180
8
20
214
2197
—
7
0
215
2217
—
10
16
205
2139
15
26
172
1800
Pathology report gross observation
24419-4 [3002256]
1.0e+00
1.8e+00
—
1.0e+50
—
1.6e+00
1.1e+00
cases:5.86%
controls:2.17%
cases:4.05%
controls:0.68%
—
—
cases:4.95%
controls:0.00%
—
—
cases:3.72%
controls:0.79%
cases:7.49%
controls:2.52%
13
48
209
2169
9
15
213
2202
—
11
0
211
2217
—
8
17
207
2138
14
46
173
1780
Medical doctor
Z2221 [2001311556]
6.3e-01
9.7e-01
—
—
—
1.6e+00
1.2e+00
cases:9.46%
controls:5.28%
cases:4.05%
controls:1.58%
—
—
—
—
—
—
cases:6.05%
controls:1.35%
cases:8.02%
controls:2.57%
21
117
201
2100
9
35
213
2182
—
—
—
13
29
202
2126
15
47
172
1779
One hour or less
ZXE00 [2001311394]
4.6e-01
8.8e-01
—
—
2.5e+00
7.1e-01
3.5e-01
cases:9.01%
controls:5.86%
cases:4.05%
controls:1.71%
—
—
—
—
cases:2.73%
controls:0.23%
cases:3.26%
controls:1.62%
cases:4.81%
controls:3.45%
20
130
202
2087
9
38
213
2179
—
—
6
5
214
2206
7
35
208
2120
9
63
178
1763
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
—
—
—
—
—
-1.0e+50
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:3.21%
controls:0.27%
—
—
—
—
—
0
6
215
2149
6
5
181
1821
Basocellular carcinoma of the skin on the torso
C44.51 [2000500800]
2.3e+00
—
—
—
—
—
1.7e+00
cases:2.70%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.60%
6
6
216
2211
—
—
—
—
—
6
11
181
1815
Naevus/mole
S82 [2002001046]
7.6e-01
2.3e+00
—
—
—
—
1.2e+00
cases:3.60%
controls:1.71%
cases:4.95%
controls:0.54%
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.86%
8
38
214
2179
11
12
211
2205
—
—
—
—
11
34
176
1792
General Surgery
2 [38004447]
2.6e-01
1.9e-01
1.4e+00
1.0e+50
2.2e+00
7.8e-01
2.2e-01
cases:19.82%
controls:15.97%
cases:5.86%
controls:4.87%
cases:2.25%
controls:0.59%
cases:5.86%
controls:0.00%
cases:2.73%
controls:0.32%
cases:9.30%
controls:4.50%
cases:14.44%
controls:11.94%
44
354
178
1863
13
108
209
2109
5
13
217
2204
13
0
209
2217
6
7
214
2204
20
97
195
2058
27
218
160
1608
Neck ultrasound examination
EP1AE [2001302284]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.38%
—
—
—
—
—
—
6
7
181
1819
Supplier / Service Provider
OMOP5117446 [33004]
-8.6e-01
-4.4e-01
—
—
—
1.6e+00
2.9e+00
cases:12.61%
controls:25.35%
cases:5.86%
controls:8.80%
—
—
—
—
—
—
cases:2.79%
controls:0.56%
cases:16.04%
controls:1.04%
28
562
194
1655
13
195
209
2022
—
—
—
6
12
209
2143
30
19
157
1807
Extensive abdominal CT
JN3BD [2001305556]
—
-1.0e+50
—
—
—
—
2.0e+00
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:4.81%
controls:0.66%
—
0
6
222
2211
—
—
—
—
9
12
178
1814
Immunohistochemistry procedure
117617002 [4035726]
6.6e-01
—
—
—
—
—
1.9e+00
cases:2.25%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
cases:6.42%
controls:1.04%
5
26
217
2191
—
—
—
—
—
12
19
175
1807
Spinalanesthesia
WX320 [2001310799]
5.5e-01
1.7e+00
—
—
—
—
2.7e-01
cases:4.50%
controls:2.66%
cases:4.05%
controls:0.77%
—
—
—
—
—
—
—
—
cases:4.28%
controls:3.29%
10
59
212
2158
9
17
213
2200
—
—
—
—
8
60
179
1766
Oncology Clinic/Center
261QX0200X [38004268]
5.4e-01
1.6e+00
—
—
—
1.0e+00
8.5e-02
cases:8.11%
controls:4.87%
cases:6.76%
controls:1.40%
—
—
—
—
—
—
cases:3.72%
controls:1.39%
cases:4.81%
controls:4.44%
18
108
204
2109
15
31
207
2186
—
—
—
8
30
207
2125
9
81
178
1745
Intravenous general anesthesia
WX404 [2001310807]
5.1e-02
—
—
—
—
—
1.6e+00
cases:2.70%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.26%
6
57
216
2160
—
—
—
—
—
11
23
176
1803
Abdominal ultrasound examination
JN3AE [2001305555]
2.8e-01
—
—
—
—
—
1.5e+00
cases:2.25%
controls:1.71%
—
—
—
—
—
—
—
—
—
—
cases:6.42%
controls:1.53%
5
38
217
2179
—
—
—
—
—
12
28
175
1798
Scheduled procedure
ZXD10 [2001311387]
3.5e-01
8.8e-01
—
—
—
7.8e-01
1.3e+00
cases:8.56%
controls:6.18%
cases:3.60%
controls:1.53%
—
—
—
—
—
—
cases:2.79%
controls:1.30%
cases:10.16%
controls:2.90%
19
137
203
2080
8
34
214
2183
—
—
—
6
28
209
2127
19
53
168
1773
cefalexin; oral
J01DB01 [21602870]
3.0e-01
2.0e-01
7.4e-01
—
—
7.6e-01
5.5e-01
cases:34.23%
controls:27.92%
cases:10.81%
controls:9.02%
cases:2.25%
controls:1.08%
—
—
—
—
cases:18.14%
controls:9.37%
cases:37.43%
controls:25.58%
76
619
146
1598
24
200
198
2017
5
24
217
2193
—
—
39
202
176
1953
70
467
117
1359
Dermatitis, unspecified
L30.9 [45572271]
1.3e+00
—
—
—
—
—
6.5e-02
cases:5.86%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
cases:3.21%
controls:3.01%
13
37
209
2180
—
—
—
—
—
6
55
181
1771
Seborrhoeic keratosis
L82 [45548208]
1.3e+00
—
—
—
—
—
1.0e+00
cases:5.86%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
cases:6.95%
controls:2.63%
13
37
209
2180
—
—
—
—
—
13
48
174
1778
More than one and less than three hours
ZXE10 [2001311401]
2.2e-01
2.8e-01
—
—
—
—
1.3e+00
cases:7.21%
controls:5.86%
cases:2.25%
controls:1.71%
—
—
—
—
—
—
—
—
cases:8.02%
controls:2.35%
16
130
206
2087
5
38
217
2179
—
—
—
—
15
43
172
1783
Physiotherapy
R4110 [2001310233]
3.1e-01
4.4e-01
-1.0e+50
—
—
1.0e+00
1.1e+00
cases:5.41%
controls:4.01%
cases:2.70%
controls:1.76%
cases:0.00%
controls:0.27%
—
—
—
—
cases:2.79%
controls:1.02%
cases:9.09%
controls:3.12%
12
89
210
2128
6
39
216
2178
0
6
222
2211
—
—
6
22
209
2133
17
57
170
1769
Medical Oncology
90 [38004507]
2.3e-01
2.5e-01
—
—
—
6.6e-01
1.1e+00
cases:4.05%
controls:3.25%
cases:2.70%
controls:2.12%
—
—
—
—
—
—
cases:4.65%
controls:2.46%
cases:9.09%
controls:3.29%
9
72
213
2145
6
47
216
2170
—
—
—
10
53
205
2102
17
60
170
1766
Coloscopy
UJF32 [2001305029]
-1.8e-01
—
—
—
—
—
1.1e+00
cases:3.15%
controls:3.74%
—
—
—
—
—
—
—
—
—
—
cases:7.49%
controls:2.68%
7
83
215
2134
—
—
—
—
—
14
49
173
1777
Plastic And Reconstructive Surgery
24 [38004467]
1.0e+00
—
—
1.0e+50
—
1.3e+00
1.0e+00
cases:6.76%
controls:2.48%
—
—
—
—
cases:12.16%
controls:0.00%
—
—
cases:4.65%
controls:1.25%
cases:6.95%
controls:2.63%
15
55
207
2162
—
—
27
0
195
2217
—
10
27
205
2128
13
48
174
1778
fusidic acid
D09AA02 [21602265]
2.5e-02
1.0e+00
—
—
—
—
1.0e+00
cases:3.60%
controls:3.52%
cases:3.60%
controls:1.31%
—
—
—
—
—
—
—
—
cases:10.70%
controls:4.22%
8
78
214
2139
8
29
214
2188
—
—
—
—
20
77
167
1749
fusidic acid; ointment
D06AX01 [21602062]
2.5e-02
1.0e+00
—
—
—
—
1.0e+00
cases:3.60%
controls:3.52%
cases:3.60%
controls:1.31%
—
—
—
—
—
—
—
—
cases:10.70%
controls:4.22%
8
78
214
2139
8
29
214
2188
—
—
—
—
20
77
167
1749
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
-1.4e-03
—
-1.0e+50
—
-1.0e+50
5.1e-01
8.7e-01
cases:4.95%
controls:4.96%
—
—
cases:0.00%
controls:0.27%
—
—
cases:0.00%
controls:0.23%
cases:3.72%
controls:2.27%
cases:11.76%
controls:5.31%
11
110
211
2107
—
0
6
222
2211
—
0
5
220
2206
8
49
207
2106
22
97
165
1729
Thorax X-ray examination
GD1AA [2001303617]
7.1e-02
1.0e+00
—
—
—
5.5e-01
8.6e-01
cases:7.66%
controls:7.17%
cases:5.86%
controls:2.21%
—
—
—
—
—
—
cases:5.12%
controls:3.02%
cases:16.04%
controls:7.45%
17
159
205
2058
13
49
209
2168
—
—
—
11
65
204
2090
30
136
157
1690
mometasone; nasal
R01AD09 [21605051]
7.9e-01
3.7e-01
—
—
—
6.6e-01
2.9e-01
cases:17.57%
controls:8.84%
cases:5.41%
controls:3.79%
—
—
—
—
—
—
cases:6.51%
controls:3.48%
cases:11.76%
controls:9.09%
39
196
183
2021
12
84
210
2133
—
—
—
14
75
201
2080
22
166
165
1660
amoxicillin; oral, parenteral
J01CA04 [21602823]
6.4e-01
4.0e-01
—
—
—
1.0e-01
6.3e-02
cases:35.14%
controls:22.15%
cases:9.01%
controls:6.22%
—
—
—
—
—
—
cases:7.91%
controls:7.19%
cases:21.93%
controls:20.87%
78
491
144
1726
20
138
202
2079
—
—
—
17
155
198
2000
41
381
146
1445
Respiratory symptom/complaint other
R29 [2002000898]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.77%
—
—
—
—
—
0
6
215
2149
0
14
187
1812
Cutaneous abscess, furuncle and carbuncle, unspecified
L02.9 [45591620]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
187
1817
ofloxacin
S01AE01 [43534856]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
6
222
2211
0
6
222
2211
—
—
—
—
0
7
187
1819
Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium
O99.89 [2000503220]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
—
Acute subendocardial myocardial infarction
I21.4 [45572081]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
2.0e-01
9.3e-01
—
—
—
—
5.3e-01
cases:2.25%
controls:1.85%
cases:2.25%
controls:0.90%
—
—
—
—
—
—
—
—
cases:5.88%
controls:3.56%
5
41
217
2176
5
20
217
2197
—
—
—
—
11
65
176
1761
nimesulide; oral
M01AX17 [21604007]
5.9e-01
—
—
—
—
—
—
cases:2.25%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
217
2189
—
—
—
—
—
—
Retinal detachment with retinal break
H33.0 [45547857]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
187
1820
Lipid panel - Serum or Plasma
100898-6 [1761868]
-2.3e-01
-4.0e-02
—
—
-1.0e+50
-5.8e-01
-9.3e-02
cases:4.95%
controls:6.13%
cases:3.60%
controls:3.74%
—
—
—
—
cases:0.00%
controls:0.45%
cases:2.33%
controls:4.08%
cases:11.76%
controls:12.76%
11
136
211
2081
8
83
214
2134
—
—
0
10
220
2201
5
88
210
2067
22
233
165
1593
linagliptin; oral
A10BH05 [40251691]
-1.0e+50
—
-1.0e+50
—
-1.0e+50
—
—
cases:0.00%
controls:0.59%
—
—
cases:0.00%
controls:0.32%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
0
13
222
2204
—
0
7
222
2210
—
0
7
220
2204
—
—
methenamine; oral
J01XX05 [21603065]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
pH of Urine
2756-5 [3015736]
3.9e-01
1.7e-01
—
—
-1.0e+50
-1.1e-01
-3.2e-02
cases:11.26%
controls:7.94%
cases:4.50%
controls:3.83%
—
—
—
—
cases:0.00%
controls:0.59%
cases:4.19%
controls:4.64%
cases:12.30%
controls:12.65%
25
176
197
2041
10
85
212
2132
—
—
0
13
220
2198
9
100
206
2055
23
231
164
1595
Cutaneous abscess, furuncle and carbuncle of other sites
L02.8 [45552968]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
187
1819
Allergy/allergic reaction NOS
A92 [2002000225]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
6
215
2149
—
Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection
70242-3 [42868716]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
8
187
1818
insulin glulisine; parenteral
A10AB06 [21600720]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
222
2207
—
—
—
—
—
—
Functional capacity evaluation
443351003 [40481051]
—
—
—
—
—
—
3.9e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:2.57%
—
—
—
—
—
—
5
47
182
1779
Unspecified acute lower respiratory infection
J22 [45586665]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
1.0e-01
4.6e-01
1.1e+00
—
—
2.7e-01
3.9e-01
cases:9.91%
controls:9.02%
cases:6.76%
controls:4.38%
cases:2.25%
controls:0.77%
—
—
—
—
cases:7.44%
controls:5.80%
cases:20.86%
controls:15.12%
22
200
200
2017
15
97
207
2120
5
17
217
2200
—
—
16
125
199
2030
39
276
148
1550
salmeterol; inhalant
R03AC12 [21603266]
2.0e+00
-1.0e+50
—
—
—
—
—
cases:2.25%
controls:0.32%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
5
7
217
2210
0
6
222
2211
—
—
—
—
—
donepezil; oral
N06DA02 [21604795]
-1.0e+50
—
-1.0e+50
—
-1.0e+50
—
—
cases:0.00%
controls:0.68%
—
—
cases:0.00%
controls:0.36%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
0
15
222
2202
—
0
8
222
2209
—
0
7
220
2204
—
—
Single live birth
Z37.0 [45571346]
6.1e-01
—
—
—
—
—
—
cases:3.60%
controls:1.98%
—
—
—
—
—
—
—
—
—
—
—
—
8
44
214
2173
—
—
—
—
—
—
Adjuvant radiotherapy
WF003 [2001310702]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
222
2207
—
—
—
—
—
—
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.8e-02
-8.4e-02
7.0e-01
—
—
3.3e-01
3.5e-01
cases:10.36%
controls:10.01%
cases:4.95%
controls:5.37%
cases:2.25%
controls:1.13%
—
—
—
—
cases:8.84%
controls:6.50%
cases:17.65%
controls:13.14%
23
222
199
1995
11
119
211
2098
5
25
217
2192
—
—
19
140
196
2015
33
240
154
1586
haemophilus influenzae B and hepatitis B
J07CA08 [21601379]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
222
2207
—
—
—
—
—
—
Migraine
N89 [2002000789]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
0
5
222
2212
—
—
—
0
7
215
2148
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
1.7e-01
-1.3e-01
—
—
—
—
4.6e-01
cases:8.11%
controls:6.90%
cases:2.70%
controls:3.07%
—
—
—
—
—
—
—
—
cases:14.44%
controls:9.64%
18
153
204
2064
6
68
216
2149
—
—
—
—
27
176
160
1650
Health maint/preventive medicine
A98 [2002000231]
-9.8e-03
2.3e-01
7.1e-02
—
5.1e-01
3.0e-01
9.1e-02
cases:39.64%
controls:39.87%
cases:33.78%
controls:28.87%
cases:5.41%
controls:5.05%
—
—
cases:9.09%
controls:5.65%
cases:35.81%
controls:29.23%
cases:56.15%
controls:53.89%
88
884
134
1333
75
640
147
1577
12
112
210
2105
—
20
125
200
2086
77
630
138
1525
105
984
82
842
Sensorineural hearing loss, bilateral
H90.3 [45576850]
2.3e-01
1.2e+00
—
—
—
6.7e-01
6.1e-01
cases:2.70%
controls:2.17%
cases:3.15%
controls:0.95%
—
—
—
—
—
—
cases:2.33%
controls:1.21%
cases:4.81%
controls:2.68%
6
48
216
2169
7
21
215
2196
—
—
—
5
26
210
2129
9
49
178
1777
Cystocele
N81.1 [45558171]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
187
1817
Calcium.ionized [Moles/volume] in Venous blood
41645-3 [3033705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
187
1819
Impotence of organic origin
N48.4 [45558161]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
Fracture of tooth root
S02.53 [2000503620]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
-1.6e-01
—
—
—
—
—
2.4e-01
cases:2.70%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
cases:3.74%
controls:2.96%
6
70
216
2147
—
—
—
—
—
7
54
180
1772
Granulocytes [#/volume] in Blood
30394-1 [3035715]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Home visit
WYA20 [2001310873]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
Surface analgesia on skin or mucosa
WX105 [2001310765]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
calcium (different salts in combination); oral
A12AA20 [21600872]
2.6e-01
4.0e-02
—
—
—
1.6e-01
4.1e-01
cases:8.56%
controls:6.72%
cases:5.86%
controls:5.64%
—
—
—
—
—
—
cases:6.98%
controls:6.03%
cases:11.76%
controls:8.16%
19
149
203
2068
13
125
209
2092
—
—
—
15
130
200
2025
22
149
165
1677
sildenafil; oral
G04BE03 [21602648]
4.4e-01
6.6e-01
—
—
—
—
3.8e-01
cases:2.70%
controls:1.76%
cases:2.25%
controls:1.17%
—
—
—
—
—
—
—
—
cases:4.28%
controls:2.96%
6
39
216
2178
5
26
217
2191
—
—
—
—
8
54
179
1772
Pelvic, hip and femur MRI examination with high intensity magnet
NE1BG [2001307800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2209
—
—
—
—
—
—
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood
88518-6 [36304997]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
0
7
222
2210
—
—
—
—
—
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
3.1e-01
—
—
—
—
—
6.4e-01
cases:2.25%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:1.42%
5
37
217
2180
—
—
—
—
—
5
26
182
1800
Orthodontic treatment/control appointment
SJX20 [2001310454]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2209
—
—
—
—
—
—
Informing family of child’s disability
SPAT1236 [2001700337]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
—
Shoulder extensive X-ray examination without contrast
NB1BA [2001307228]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2209
—
—
—
—
—
—
Microscopic observation [Identifier] in Vaginal fluid by Gram stain
14361-0 [3000855]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
Examination of eyes and vision
Z01.0 [45566391]
1.9e-01
—
-1.0e+50
—
-1.0e+50
—
8.4e-02
cases:2.70%
controls:2.26%
—
—
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.23%
—
—
cases:3.21%
controls:2.96%
6
50
216
2167
—
0
5
222
2212
—
0
5
220
2206
—
6
54
181
1772
dexamethasone; oral, parenteral
H02AB02 [21602730]
2.7e-01
—
—
—
—
—
7.6e-01
cases:3.15%
controls:2.44%
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:2.30%
7
54
215
2163
—
—
—
—
—
9
42
178
1784
Neurology
13 [38004458]
-4.0e-01
—
-1.0e+50
—
—
-7.8e-01
3.5e-01
cases:6.76%
controls:9.79%
—
—
cases:0.00%
controls:0.41%
—
—
—
—
cases:2.33%
controls:4.92%
cases:12.83%
controls:9.36%
15
217
207
2000
—
0
9
222
2208
—
—
5
106
210
2049
24
171
163
1655
Psychologist
Z2445 [2001311558]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
8.6e-01
-1.0e+50
—
—
—
—
—
cases:3.15%
controls:1.35%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
7
30
215
2187
0
5
222
2212
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
5.0e-01
2.9e-01
—
—
—
7.7e-01
6.9e-01
cases:6.31%
controls:3.92%
cases:2.70%
controls:2.03%
—
—
—
—
—
—
cases:3.26%
controls:1.53%
cases:6.95%
controls:3.61%
14
87
208
2130
6
45
216
2172
—
—
—
7
33
208
2122
13
66
174
1760
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
4.2e-01
—
—
—
—
—
-3.4e-01
cases:4.05%
controls:2.71%
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:3.72%
9
60
213
2157
—
—
—
—
—
5
68
182
1758
Calcium [Moles/time] in 24 hour Urine
14637-3 [3010838]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
aciclovir; oral, parenteral
J05AB01 [21603131]
6.7e-01
—
—
—
—
7.8e-01
7.4e-01
cases:4.50%
controls:2.35%
—
—
—
—
—
—
—
—
cases:2.79%
controls:1.30%
cases:5.88%
controls:2.90%
10
52
212
2165
—
—
—
—
6
28
209
2127
11
53
176
1773
Depressive episode
F32 [45595904]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
7
215
2148
—
Polyarthrosis, unspecified
M15.9 [45543481]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
0
5
222
2212
—
—
—
—
0
8
187
1818
Peanut IgE Ab [Units/volume] in Serum
6206-7 [3012494]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
nystatin
D01AA01 [21601911]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
Boil/carbuncle
S10 [2002000975]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
0
14
222
2203
0
6
222
2211
—
—
—
—
—
Tachycardia, unspecified
R00.0 [45606790]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
10
187
1816
Transient cerebral ischaemic attack, unspecified
G45.9 [45542892]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.08%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
0
24
222
2193
0
7
222
2210
—
—
—
0
8
215
2147
—
Biopsy of endometrium
LCA06 [2001306551]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
0
12
215
2143
—
Mouth breathing
R06.5 [45573006]
1.9e+00
—
—
—
—
—
—
cases:2.70%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
6
9
216
2208
—
—
—
—
—
—
Obesity
T82 [2002001125]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
11
187
1815
Postpartum check-up
SPAT1380 [2001700480]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.21%
controls:1.15%
—
—
—
—
—
—
6
21
181
1805
C reactive protein [Mass/volume] in Body fluid
16503-5 [3035320]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
0
5
222
2212
—
—
—
—
0
5
215
2150
—
ketoprofen; ointment
M02AA10 [21604046]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
12
222
2205
—
—
—
—
—
Choriogonadotropin [Units/volume] in Serum or Plasma
19080-1 [3018171]
6.1e-01
—
—
—
—
—
—
cases:2.70%
controls:1.49%
—
—
—
—
—
—
—
—
—
—
—
—
6
33
216
2184
—
—
—
—
—
—
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
Basic examination of mouth
SAA02 [2001310275]
9.2e-02
1.7e-01
-1.0e+50
—
—
2.2e-01
4.5e-02
cases:19.82%
controls:18.40%
cases:8.56%
controls:7.35%
cases:0.00%
controls:0.50%
—
—
—
—
cases:7.91%
controls:6.45%
cases:23.53%
controls:22.73%
44
408
178
1809
19
163
203
2054
0
11
222
2206
—
—
17
139
198
2016
44
415
143
1411
Gas panel - Venous blood
24339-4 [3000991]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
9
222
2208
—
—
—
0
10
215
2145
—
EKG study
11524-6 [3013512]
-4.0e-01
2.3e-01
—
—
—
2.9e-02
-4.6e-01
cases:4.05%
controls:5.91%
cases:3.15%
controls:2.53%
—
—
—
—
—
—
cases:3.72%
controls:3.62%
cases:5.88%
controls:8.98%
9
131
213
2086
7
56
215
2161
—
—
—
8
78
207
2077
11
164
176
1662
Supervision of normal pregnancy
Z34 [45566419]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.38%
0
15
222
2202
0
7
222
2210
—
—
—
0
7
215
2148
0
7
187
1819
Ocular fundus photography for diabetic retinopathy screening
CL2S4 [2001301465]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
187
1819
Three-surface restoration
SFA30 [2001310360]
-3.3e-01
-6.1e-02
—
—
-1.0e+50
1.6e-01
-3.9e-01
cases:5.41%
controls:7.35%
cases:2.25%
controls:2.39%
—
—
—
—
cases:0.00%
controls:0.27%
cases:3.26%
controls:2.78%
cases:6.95%
controls:9.91%
12
163
210
2054
5
53
217
2164
—
—
0
6
220
2205
7
60
208
2095
13
181
174
1645
Orthostatic hypotension
I95.1 [45605872]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
0
8
222
2209
—
—
—
—
—
0
10
187
1816
Stomach Pathology biopsy report
66114-0 [40768797]
2.5e-01
—
—
—
—
1.6e+00
4.2e-01
cases:2.70%
controls:2.12%
—
—
—
—
—
—
—
—
cases:3.26%
controls:0.65%
cases:3.21%
controls:2.14%
6
47
216
2170
—
—
—
—
7
14
208
2141
6
39
181
1787
Neck artery ultrasound examination with Doppler method
PA6DE [2001308705]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
222
2202
—
—
—
—
—
—
Sexual health counselling
SPAT1308 [2001700409]
3.7e-01
—
—
—
—
—
—
cases:4.05%
controls:2.84%
—
—
—
—
—
—
—
—
—
—
—
—
9
63
213
2154
—
—
—
—
—
—
General medical examination
Z00.0 [45585791]
-3.5e-01
—
—
—
—
—
2.5e-01
cases:2.25%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
cases:3.21%
controls:2.52%
5
70
217
2147
—
—
—
—
—
6
46
181
1780
Epilepsy and comparable convulsive disorders
111 [2001600111]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
1.0e-02
5.8e-02
-1.0e+50
—
—
1.5e-01
2.4e-01
cases:8.56%
controls:8.48%
cases:4.05%
controls:3.83%
cases:0.00%
controls:0.59%
—
—
—
—
cases:4.65%
controls:4.04%
cases:12.83%
controls:10.35%
19
188
203
2029
9
85
213
2132
0
13
222
2204
—
—
10
87
205
2068
24
189
163
1637
duloxetine; oral
N06AX21 [21604749]
3.6e-01
7.9e-01
—
—
—
4.9e-01
3.7e-01
cases:3.15%
controls:2.21%
cases:2.25%
controls:1.04%
—
—
—
—
—
—
cases:2.33%
controls:1.44%
cases:3.21%
controls:2.25%
7
49
215
2168
5
23
217
2194
—
—
—
5
31
210
2124
6
41
181
1785
Abdominal X-ray examination without contrast
JN3AA [2001305553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2208
—
—
—
—
—
—
valsartan; oral
C09CA03 [21601826]
5.7e-01
—
—
—
-1.0e+50
—
4.6e-01
cases:3.15%
controls:1.80%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
cases:2.67%
controls:1.70%
7
40
215
2177
—
—
—
0
10
220
2201
—
5
31
182
1795
ephedrine; oral
R03CA02 [21603304]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
12
222
2205
—
—
—
—
—
0
5
187
1821
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
6.7e-01
—
—
—
—
-1.0e+50
—
cases:2.70%
controls:1.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
6
31
216
2186
—
—
—
—
0
7
215
2148
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
14
222
2203
—
—
—
0
10
215
2145
—
Stress incontinence
N39.3 [45539046]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
0
21
187
1805
Skin colour change
S08 [2002000973]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.77%
—
—
—
—
—
0
5
215
2150
0
14
187
1812
Segmented neutrophils/Leukocytes in Blood
26505-8 [3017354]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Pneumonia, unspecified
J18.9 [45601123]
-1.4e-01
—
—
—
—
—
3.3e-01
cases:2.25%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:3.50%
5
57
217
2160
—
—
—
—
—
9
64
178
1762
lymecycline; oral, parenteral
J01AA04 [21602802]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
10
222
2207
—
—
—
0
8
215
2147
—
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
1.6e-01
3.0e-01
—
—
—
3.4e-01
1.3e-01
cases:21.17%
controls:18.58%
cases:19.37%
controls:15.07%
—
—
—
—
—
—
cases:20.93%
controls:15.92%
cases:31.55%
controls:28.81%
47
412
175
1805
43
334
179
1883
—
—
—
45
343
170
1812
59
526
128
1300
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
-5.1e-02
-2.4e-01
—
—
—
6.1e-02
5.0e-01
cases:7.66%
controls:8.03%
cases:4.05%
controls:5.10%
—
—
—
—
—
—
cases:5.12%
controls:4.83%
cases:19.79%
controls:12.98%
17
178
205
2039
9
113
213
2104
—
—
—
11
104
204
2051
37
237
150
1589
Cystoscopy
UKC02 [2001306005]
8.3e-01
—
—
—
—
—
9.2e-01
cases:4.05%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:4.28%
controls:1.75%
9
40
213
2177
—
—
—
—
—
8
32
179
1794
Midwife
Z3232 [2001311563]
7.7e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:3.15%
controls:1.49%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
7
33
215
2184
0
10
222
2207
—
—
—
0
5
215
2150
—
chlordiazepoxide; oral, parenteral
N05BA02 [21604567]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
6
222
2211
—
—
—
—
—
0
5
187
1821
Irritable bowel syndrome
K58 [45572218]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
187
1817
Bilateral
ZXA10 [2001311348]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
0
13
222
2204
—
—
—
0
9
215
2146
—
Other malignant neoplasm of kidney, except renal pelvis
C64.88 [2000501096]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
olanzapine and samidorphan
N05AH53 [955100]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
—
zinc bandage without supplements
D09AB01 [21602278]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
187
1819
Application of soft bandage
SPAT1211 [2001700312]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:1.15%
—
—
—
—
—
0
5
215
2150
0
21
187
1805
CT angiography of head and neck vasculature
PA7AD [2001300233]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2209
—
—
—
—
—
—
Intravenous administration of medicine
SPAT1255 [2001700356]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
0
7
222
2210
—
—
—
—
—
0
16
187
1810
acetylsalicylic acid; oral
B01AC06 [21600991]
—
—
—
—
-1.0e+50
—
5.2e-02
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
cases:3.74%
controls:3.56%
—
—
—
—
0
15
220
2196
—
7
65
180
1761
Contusion of knee
S80.0 [45569633]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
Assessment of need for aid
SPAT1229 [2001700330]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
0
9
222
2208
0
10
222
2207
—
—
—
0
6
215
2149
—
Fracture of lumbar vertebra
S32.0 [45583057]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
Post-traumatic stress disorder
F43.1 [45595909]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
10
222
2207
—
—
—
—
—
0
5
187
1821
Routine child health examination
Z00.1 [45561606]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-1.3e-01
-1.4e-03
—
—
-1.0e+50
-1.2e-02
1.7e-01
cases:5.41%
controls:6.13%
cases:3.15%
controls:3.16%
—
—
—
—
cases:0.00%
controls:0.41%
cases:3.26%
controls:3.29%
cases:9.63%
controls:8.27%
12
136
210
2081
7
70
215
2147
—
—
0
9
220
2202
7
71
208
2084
18
151
169
1675
IgG subclass 2 [Mass/volume] in Serum
2467-9 [3028192]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
terbinafine; ointment
D01AE15 [21601954]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
0
12
215
2143
—
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
7.9e-01
—
—
—
—
—
8.1e-01
cases:2.25%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:1.20%
5
23
217
2194
—
—
—
—
—
5
22
182
1804
sulfadiazine and trimethoprim
J01EE02 [21602962]
7.5e-02
—
—
—
—
—
—
cases:3.15%
controls:2.93%
—
—
—
—
—
—
—
—
—
—
—
—
7
65
215
2152
—
—
—
—
—
—
Extensive health check-up on eighth grade
SPAT1386 [2001700486]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
9
222
2208
0
8
222
2209
—
—
—
—
—
Orthodontic treatment/control appointment, short
SJX10 [2001310452]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
222
2203
—
—
—
—
—
—
Mucopurulent conjunctivitis
H10.0 [45596007]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
7
215
2148
—
Examination for recruitment to armed forces
Z02.3 [45576125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
222
2203
—
—
—
—
—
—
Fear sexually transm disease male
Y25 [2002001393]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
triamcinolone; nasal
R01AD11 [21605052]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.49%
—
—
—
—
—
0
5
215
2150
0
9
187
1817
Fall on and from stairs and steps
W10 [45756250]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
8
187
1818
Occlusion and stenosis of carotid artery
I65.2 [45552808]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
7
222
2210
0
5
222
2212
—
—
—
—
0
5
187
1821
Emergency use of U07.1 | COVID-19, virus identified
U07.1 [45756093]
—
—
—
—
—
—
1.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:4.22%
—
—
—
—
—
—
9
77
178
1749
Foot and toes extensive X-ray examination
NH3BA [2001308270]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
187
1817
Emergency Room Visit
ER [9203]
1.1e-01
3.9e-01
6.0e-01
1.0e+50
—
3.6e-01
2.6e-01
cases:36.49%
controls:34.06%
cases:14.86%
controls:10.60%
cases:3.15%
controls:1.76%
cases:2.70%
controls:0.00%
—
—
cases:16.28%
controls:11.97%
cases:34.22%
controls:28.59%
81
755
141
1462
33
235
189
1982
7
39
215
2178
6
0
216
2217
—
35
258
180
1897
64
522
123
1304
Periodontal treatment by dental hygienist
SDE02 [2001310350]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.74%
controls:3.29%
—
—
—
—
—
—
7
60
180
1766
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
2.0e-01
4.8e-01
—
—
—
5.1e-01
3.6e-01
cases:9.01%
controls:7.53%
cases:3.60%
controls:2.26%
—
—
—
—
—
—
cases:3.72%
controls:2.27%
cases:9.09%
controls:6.52%
20
167
202
2050
8
50
214
2167
—
—
—
8
49
207
2106
17
119
170
1707
Breathing problem other
R04 [2002000885]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
latanoprost
S01EE01 [21603710]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
6
222
2211
—
0
9
220
2202
—
—
Rubber band ligature of haemorrhoids or prolapse of mucosa
JHB30 [2001305142]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
187
1819
Pars plana or pars plicata vitrectomy
CKD65 [2001301417]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Menopausal and other perimenopausal disorders
N95 [45582429]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
tretinoin; ointment
D10AD01 [21602293]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
10
215
2145
—
Knee extensive X-ray examination
NG1BA [2001308053]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
187
1820
Simple examination of mouth
SAA01 [2001310274]
2.4e-01
-3.8e-02
—
—
—
-4.2e-02
7.9e-02
cases:26.13%
controls:21.83%
cases:9.46%
controls:9.79%
—
—
—
—
—
—
cases:10.23%
controls:10.63%
cases:28.88%
controls:27.27%
58
484
164
1733
21
217
201
2000
—
—
—
22
229
193
1926
54
498
133
1328
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.5e-01
7.1e-01
—
—
-1.0e+50
4.0e-01
4.2e-01
cases:4.95%
controls:4.29%
cases:2.70%
controls:1.35%
—
—
—
—
cases:0.00%
controls:0.23%
cases:2.33%
controls:1.58%
cases:6.42%
controls:4.33%
11
95
211
2122
6
30
216
2187
—
—
0
5
220
2206
5
34
210
2121
12
79
175
1747
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.74%
controls:2.30%
—
—
—
—
—
—
7
42
180
1784
Conjunctivitis, unspecified
H10.9 [45591253]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.26%
—
—
—
—
—
—
0
23
187
1803
tibolone; oral
G03CX01 [21602536]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
9
222
2208
—
—
—
—
—
0
7
187
1819
Leg/thigh symptom/complaint
L14 [2002000638]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.81%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
18
222
2199
0
8
222
2209
—
—
—
—
—
Counselling and guidance related to growth and development
SPAT1303 [2001700404]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
timolol, combinations
S01ED51 [21603705]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
Change in bowel habit
R19.4 [45573017]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2208
—
—
—
—
—
—
Campylobacter sp identified in Specimen by Organism specific culture
6332-1 [3012568]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
187
1817
Chronic arrhythmias
207 [2001600205]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
Urination problems other
U05 [2002001140]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
9
222
2208
—
—
—
—
—
0
9
187
1817
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1.2e+00
-1.0e+50
—
—
—
—
5.3e-01
cases:4.05%
controls:1.26%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.21%
controls:1.92%
9
28
213
2189
0
11
222
2206
—
—
—
—
6
35
181
1791
Malignant neoplasm prostate
Y77 [2002001445]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
Psychiatry
26 [38004469]
-3.9e-02
4.4e-02
5.2e-01
-1.0e+50
—
5.8e-01
2.1e-01
cases:6.31%
controls:6.54%
cases:3.15%
controls:3.02%
cases:2.25%
controls:1.35%
cases:0.00%
controls:0.23%
—
—
cases:5.58%
controls:3.20%
cases:6.95%
controls:5.70%
14
145
208
2072
7
67
215
2150
5
30
217
2187
0
5
222
2212
—
12
69
203
2086
13
104
174
1722
Multidisciplinary treatment meeting
WZC20 [2001310890]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
222
2204
—
—
—
—
—
—
Blood transfusion
WW500 [2001310603]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
6
215
2149
—
Dysthymia
F34.1 [45586238]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.66%
—
—
—
—
—
0
8
215
2147
0
12
187
1814
Decompression and freeing of adhesions of peripheral nerve: other or unspecified
ACC59 [2001300650]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
Chronic gastritis, unspecified
K29.5 [45562484]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2209
—
—
—
—
—
—
Parkinson disease
G20 [45538098]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
Orthodontics
143 [44777673]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
—
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
-1.5e-01
1.0e+00
—
—
—
-1.0e+50
-2.4e-01
cases:2.25%
controls:2.62%
cases:2.25%
controls:0.81%
—
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:3.21%
controls:4.05%
5
58
217
2159
5
18
217
2199
—
—
—
0
15
215
2140
6
74
181
1752
omeprazole; oral, parenteral
A02BC01 [21600096]
—
5.2e-01
—
—
-1.0e+50
—
2.1e-02
—
—
cases:2.70%
controls:1.62%
—
—
—
—
cases:0.00%
controls:0.41%
—
—
cases:3.74%
controls:3.67%
—
6
36
216
2181
—
—
0
9
220
2202
—
7
67
180
1759
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
2.7e-01
—
—
—
—
—
2.8e-01
cases:3.15%
controls:2.44%
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:2.03%
7
54
215
2163
—
—
—
—
—
5
37
182
1789
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
1.2e-01
-1.4e-03
-1.0e+50
—
-1.0e+50
—
-4.0e-01
cases:4.05%
controls:3.61%
cases:2.25%
controls:2.26%
cases:0.00%
controls:0.41%
—
—
cases:0.00%
controls:0.45%
—
—
cases:2.67%
controls:3.94%
9
80
213
2137
5
50
217
2167
0
9
222
2208
—
0
10
220
2201
—
5
72
182
1754
Base excess in Capillary blood by calculation
1926-5 [3003129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
187
1819
Contusion of finger(s) without damage to nail
S60.0 [45535417]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
0
6
222
2211
—
—
—
—
0
5
215
2150
—
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
1.0e+00
—
—
—
—
—
—
cases:3.15%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
—
—
7
26
215
2191
—
—
—
—
—
—
trimethoprim; oral, parenteral
J01EA01 [21602931]
-1.0e-01
—
—
—
—
4.6e-01
-6.4e-01
cases:5.86%
controls:6.45%
—
—
—
—
—
—
—
—
cases:2.33%
controls:1.48%
cases:3.74%
controls:6.85%
13
143
209
2074
—
—
—
—
5
32
210
2123
7
125
180
1701
Panic disorder [episodic paroxysmal anxiety]
F41.0 [45562047]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
7
222
2210
—
—
—
—
—
0
7
187
1819
pantoprazole; oral, parenteral
A02BC02 [21600097]
1.4e-01
3.1e-01
3.1e-01
—
—
1.2e-01
2.5e-01
cases:18.02%
controls:16.01%
cases:10.36%
controls:7.85%
cases:2.25%
controls:1.67%
—
—
—
—
cases:9.30%
controls:8.35%
cases:21.39%
controls:17.52%
40
355
182
1862
23
174
199
2043
5
37
217
2180
—
—
20
180
195
1975
40
320
147
1506
Supervision of normal first pregnancy
Z34.0 [45595500]
7.7e-01
-1.0e+50
—
—
—
—
—
cases:3.15%
controls:1.49%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
7
33
215
2184
0
12
222
2205
—
—
—
—
—
Zoster [herpes zoster]
B02 [45552205]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
5.5e-01
5.9e-01
—
—
—
—
-2.5e-01
cases:3.60%
controls:2.12%
cases:2.25%
controls:1.26%
—
—
—
—
—
—
—
—
cases:3.74%
controls:4.76%
8
47
214
2170
5
28
217
2189
—
—
—
—
7
87
180
1739
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.8e-02
-1.0e-01
7.0e-01
—
—
3.4e-01
3.5e-01
cases:10.36%
controls:10.01%
cases:4.95%
controls:5.46%
cases:2.25%
controls:1.13%
—
—
—
—
cases:8.84%
controls:6.45%
cases:17.65%
controls:13.09%
23
222
199
1995
11
121
211
2096
5
25
217
2192
—
—
19
139
196
2016
33
239
154
1587
Sampling
SPAT1263 [2001700364]
3.8e-03
-2.9e-01
—
—
—
6.9e-02
-1.5e-03
cases:9.46%
controls:9.43%
cases:2.70%
controls:3.56%
—
—
—
—
—
—
cases:3.72%
controls:3.48%
cases:9.63%
controls:9.64%
21
209
201
2008
6
79
216
2138
—
—
—
8
75
207
2080
18
176
169
1650
natamycin
D01AA02 [21601912]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
—
ziprasidone; oral, parenteral
N05AE04 [21604529]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
—
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
Alzheimer disease
G30 [45538101]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
labetalol; oral, parenteral
C07AG01 [21601699]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
187
1820
Thorax CT examination
GD1AD [2001303618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
Combined vitrectomy and procedure on lens through pars plana
CKD94 [2001301426]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Acute pharyngitis, unspecified
J02.9 [45538472]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
0
6
222
2211
—
—
—
—
0
17
187
1809
insulin aspart; parenteral
A10AB05 [21600719]
1.5e-01
-6.1e-02
—
—
—
—
—
cases:2.70%
controls:2.35%
cases:2.25%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
6
52
216
2165
5
53
217
2164
—
—
—
—
—
Iron deficiency anaemia, unspecified
D50.9 [45605373]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
0
12
215
2143
—
Epilepsy
G40 [45595935]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
7
222
2210
—
—
—
—
—
0
5
187
1821
Acute stress reaction
P02 [2002000799]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
insulin aspart; parenteral
A10AD05 [21600733]
1.3e-01
-8.0e-02
—
—
—
—
—
cases:2.70%
controls:2.39%
cases:2.25%
controls:2.44%
—
—
—
—
—
—
—
—
—
—
6
53
216
2164
5
54
217
2163
—
—
—
—
—
tizanidine; oral
M03BX02 [21604116]
2.5e-01
1.4e-01
—
—
—
2.9e-01
-9.7e-02
cases:17.12%
controls:13.80%
cases:4.95%
controls:4.33%
—
—
—
—
—
—
cases:6.05%
controls:4.59%
cases:11.76%
controls:12.81%
38
306
184
1911
11
96
211
2121
—
—
—
13
99
202
2056
22
234
165
1592
plastic IUD with progestogen; implant
G02BA03 [21602449]
-2.9e-01
—
—
—
—
7.1e-01
5.3e-01
cases:2.25%
controls:2.98%
—
—
—
—
—
—
—
—
cases:2.33%
controls:1.16%
cases:4.81%
controls:2.90%
5
66
217
2151
—
—
—
—
5
25
210
2130
9
53
178
1773
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
1.0e+00
—
—
—
—
—
-1.0e+50
cases:2.70%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
6
22
216
2195
—
—
—
—
—
0
18
187
1808
Other complicated additional procedure necessary for restorative treatment
SFC92 [2001310370]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
8
222
2209
0
7
222
2210
—
—
—
—
—
Impacted cerumen
H61.2 [45562307]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2211
—
—
—
—
—
glycerol; rectal
A06AG04 [21600587]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
7.4e-01
-1.0e+50
—
—
—
—
—
cases:2.25%
controls:1.08%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
5
24
217
2193
0
13
222
2204
—
—
—
—
—
Clinical photography of mouth and teeth
SBB00 [2001310298]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
Other physical therapy
Z50.1 [45600331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
8
187
1818
fludrocortisone and antiinfectives
S03CA05 [21605209]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Treatment plan or consultation
WZC00 [2001310885]
3.4e-01
—
—
—
—
5.0e-01
2.0e-01
cases:6.31%
controls:4.56%
—
—
—
—
—
—
—
—
cases:2.79%
controls:1.72%
cases:6.42%
controls:5.31%
14
101
208
2116
—
—
—
—
6
37
209
2118
12
97
175
1729
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2208
—
—
—
—
—
—
Breast, unspecified
C50.99 [2000501021]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
Other general examinations
Z00.8 [45581001]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
6
215
2149
—
Retained molar with obstruction in the lower jaw
K01.17 [2000502662]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
Ear pain/earache
H01 [2002000475]
—
—
—
—
—
-1.0e+50
8.0e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:4.28%
controls:1.97%
—
—
—
—
—
0
15
215
2140
8
36
179
1790
Psychosocial counselling and guidance
SPAT1307 [2001700408]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:1.20%
—
0
10
222
2207
—
—
—
0
5
215
2150
0
22
187
1804
Infiltration anesthesia
WX110 [2001310767]
4.5e-02
1.5e-01
—
—
1.1e+00
6.7e-01
2.5e-01
cases:19.37%
controls:18.67%
cases:8.11%
controls:7.08%
—
—
—
—
cases:3.18%
controls:1.09%
cases:14.42%
controls:7.94%
cases:27.27%
controls:22.56%
43
414
179
1803
18
157
204
2060
—
—
7
24
213
2187
31
171
184
1984
51
412
136
1414
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
0
23
222
2194
—
—
—
—
—
Erosion of teeth
K03.2 [45572183]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
9
222
2208
—
—
—
—
—
0
7
187
1819
Neoplasm of uncertain or unknown behaviour: Kidney
D41.0 [45581311]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
187
1820
Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection
82198-3 [21493466]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
8
187
1818
Non-real-time text-based remote communication
ZYC05 [2001311583]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
The fear of childbirth
O99.80 [2000503219]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
8
215
2147
—
hydrochlorothiazide; oral
C03AA03 [21601466]
4.1e-01
—
-1.0e+50
—
-1.0e+50
—
6.6e-01
cases:2.70%
controls:1.80%
—
—
cases:0.00%
controls:0.32%
—
—
cases:0.00%
controls:0.41%
—
—
cases:3.74%
controls:1.97%
6
40
216
2177
—
0
7
222
2210
—
0
9
220
2202
—
7
36
180
1790
Allergic rhinitis, unspecified
J30.4 [45548110]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
4.8e-02
-9.3e-02
7.0e-01
—
—
3.3e-01
3.4e-01
cases:10.36%
controls:9.92%
cases:4.95%
controls:5.41%
cases:2.25%
controls:1.13%
—
—
—
—
cases:8.84%
controls:6.54%
cases:17.65%
controls:13.20%
23
220
199
1997
11
120
211
2097
5
25
217
2192
—
—
19
141
196
2014
33
241
154
1585
Psychiatric treatment plan, standard
ICB01 [2001304098]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.71%
0
8
222
2209
—
—
—
—
0
5
215
2150
0
13
187
1813
Asthma
J45 [45596282]
4.9e-01
—
—
—
—
—
8.4e-02
cases:4.05%
controls:2.53%
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:2.46%
9
56
213
2161
—
—
—
—
—
5
45
182
1781
Insertion of intrauterine device
TLC00 [2001306647]
1.4e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:2.70%
controls:0.68%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
6
15
216
2202
0
6
222
2211
—
—
—
0
5
215
2150
—
Dyspnoea
R06.0 [45558449]
2.8e-01
—
—
—
—
—
—
cases:4.50%
controls:3.43%
—
—
—
—
—
—
—
—
—
—
—
—
10
76
212
2141
—
—
—
—
—
—
SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
26975-3 [3025245]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
8
187
1818
pH of Serum or Plasma
2753-2 [3018418]
-2.0e-01
—
—
—
-1.0e+50
1.3e-01
6.0e-01
cases:4.05%
controls:4.92%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:3.72%
controls:3.29%
cases:13.37%
controls:7.83%
9
109
213
2108
—
—
—
0
9
220
2202
8
71
207
2084
25
143
162
1683
Residual foreign body in soft tissue
M79.5 [45533938]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
7
222
2210
—
—
—
—
—
0
5
187
1821
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
215
2150
—
Assessment of vision
XCW10 [2001301503]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Nursing episode
950 [44777714]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:2.35%
—
—
—
—
—
—
5
43
182
1783
Emergency Medicine
93 [38004510]
-3.0e-02
4.1e-01
—
—
1.1e+00
2.0e-01
2.8e-01
cases:12.61%
controls:12.95%
cases:9.91%
controls:6.81%
—
—
—
—
cases:2.73%
controls:0.90%
cases:9.30%
controls:7.75%
cases:26.20%
controls:21.19%
28
287
194
1930
22
151
200
2066
—
—
6
20
214
2191
20
167
195
1988
49
387
138
1439
Medication, disinfection of root canals
SGC00 [2001310392]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
8
215
2147
—
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
11
222
2206
—
—
—
—
—
0
6
187
1820
Polysomnography
SPAT1377 [2001700478]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
10
222
2207
—
—
—
—
—
0
7
187
1819
Mild cognitive disorder
F06.7 [45605450]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
5
222
2212
—
—
—
—
—
0
6
187
1820
Constipation
D12 [2002000311]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
187
1821
Gonarthrosis, unspecified
M17.9 [45606128]
—
—
—
—
—
2.1e+00
5.7e-01
—
—
—
—
—
—
—
—
—
—
cases:2.33%
controls:0.28%
cases:2.67%
controls:1.53%
—
—
—
—
—
5
6
210
2149
5
28
182
1798
insulin detemir; parenteral
A10AE05 [21600740]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
9
222
2208
—
0
6
220
2205
—
—
desonide
D07AB08 [21602112]
6.7e-01
-1.0e+50
—
—
—
—
6.8e-01
cases:2.70%
controls:1.40%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:2.67%
controls:1.37%
6
31
216
2186
0
11
222
2206
—
—
—
—
5
25
182
1801
insulin lispro; parenteral
A10AB04 [21600718]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.07%
cases:0.00%
controls:1.85%
cases:0.00%
controls:0.45%
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:1.67%
cases:0.00%
controls:1.92%
0
46
222
2171
0
41
222
2176
0
10
222
2207
—
0
8
220
2203
0
36
215
2119
0
35
187
1791
Pulmonary Disease
29 [38004472]
-5.7e-02
2.9e-01
—
—
—
3.4e-01
6.1e-02
cases:6.76%
controls:7.13%
cases:5.41%
controls:4.10%
—
—
—
—
—
—
cases:5.12%
controls:3.71%
cases:9.09%
controls:8.60%
15
158
207
2059
12
91
210
2126
—
—
—
11
80
204
2075
17
157
170
1669
venlafaxine; oral
N06AX16 [21604745]
—
—
—
—
—
1.1e+00
9.1e-01
—
—
—
—
—
—
—
—
—
—
cases:3.26%
controls:1.07%
cases:3.21%
controls:1.31%
—
—
—
—
—
7
23
208
2132
6
24
181
1802
atorvastatin; oral
C10AA05 [21601860]
-2.0e-01
2.8e-01
—
—
—
1.7e-01
8.6e-02
cases:6.76%
controls:8.12%
cases:8.56%
controls:6.59%
—
—
—
—
—
—
cases:7.91%
controls:6.73%
cases:11.76%
controls:10.90%
15
180
207
2037
19
146
203
2071
—
—
—
17
145
198
2010
22
199
165
1627
Audiometric test
21727005 [4071702]
1.5e-01
—
—
—
—
—
—
cases:2.25%
controls:1.94%
—
—
—
—
—
—
—
—
—
—
—
—
5
43
217
2174
—
—
—
—
—
—
Ear symptom/complaint other
H29 [2002000484]
—
—
—
—
—
—
2.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.67%
controls:2.08%
—
—
—
—
—
—
5
38
182
1788
acitretin; oral
D05BB02 [21602051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
Foreign body in skin
S15 [2002000980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
12
187
1814
econazole; vaginal
G01AF05 [21602395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2210
—
—
—
—
—
—
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:1.37%
0
6
222
2211
0
5
222
2212
—
—
—
0
7
215
2148
0
25
187
1801
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.5e-01
1.1e+00
—
—
—
—
5.1e-01
cases:2.25%
controls:1.94%
cases:2.70%
controls:0.95%
—
—
—
—
—
—
—
—
cases:5.88%
controls:3.61%
5
43
217
2174
6
21
216
2196
—
—
—
—
11
66
176
1760
dexamethasone
S03BA01 [21605201]
4.2e-01
—
—
—
-1.0e+50
-1.0e+50
2.6e-01
cases:3.60%
controls:2.39%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:1.11%
cases:4.28%
controls:3.34%
8
53
214
2164
—
—
—
0
6
220
2205
0
24
215
2131
8
61
179
1765
pregabalin; oral
N02BF02 [955152]
6.5e-02
4.9e-01
—
—
—
4.7e-01
4.9e-01
cases:3.60%
controls:3.38%
cases:2.70%
controls:1.67%
—
—
—
—
—
—
cases:2.79%
controls:1.76%
cases:5.35%
controls:3.34%
8
75
214
2142
6
37
216
2180
—
—
—
6
38
209
2117
10
61
177
1765
Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
50797-0 [3029379]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
187
1819
Hystero-salpingography with ultrasound
LC2HE [2001306546]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
Neoplasm of uncertain or unknown behaviour: Breast
D48.6 [45605370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2212
—
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
3.6e-01
—
-1.0e+50
—
—
—
4.2e-01
cases:2.25%
controls:1.58%
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:4.28%
controls:2.85%
5
35
217
2182
—
0
5
222
2212
—
—
—
8
52
179
1774
Lactate [Moles/volume] in Blood
32693-4 [3047181]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
0
9
222
2208
—
—
—
—
0
5
215
2150
—
Type 1 diabetes mellitus, With renal complications
E10.2 [45586137]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
11
222
2206
0
7
222
2210
—
—
—
—
0
7
187
1819
Exposure to unspecified factor
X59 [45756412]
8.4e-02
—
—
—
—
—
—
cases:2.25%
controls:2.07%
—
—
—
—
—
—
—
—
—
—
—
—
5
46
217
2171
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
143
835
2.94
13.71
3.2
2.1
—
—
—
0
0
62
256
2.96
11.00
1.8
1.2
—
—
—
0
0
36
160
2.49
5.33
1.4
1.3
—
—
—
0
0
23
83
2.97
5.05
1.7
1.2
—
—
—
0
0
115
847
1.73
3.97
2.4
2.0
98.28
95.79
pmol/l
0.22
65
439
26
116
2.40
3.81
3.5
3.1
171.46
254.56
ng/l
0.64
26
105
58
363
1.80
3.46
4.2
3.5
72.32
315.91
ng/l
1.55
44
256
109
823
1.63
3.21
4.9
4.4
36.03
36.00
g/l
0.02
99
778
81
572
1.65
3.09
2.9
3.0
0.18
0.42
e6/l
1.59
59
417
121
945
1.60
3.05
5.8
6.6
1.21
1.21
mmol/l
0.17
109
829
51
322
1.75
2.92
2.6
3.0
3.32
2.96
e6/l
0.07
19
153
212
1950
2.41
2.71
16.0
14.8
24.34
22.59
mg/l
0.30
176
1581
36
212
1.83
2.59
1.8
2.7
5.58
6.32
umol/l
0.30
29
184
81
596
1.56
2.53
3.5
3.9
7.39
7.39
ph
0.16
58
419
127
1039
1.51
2.38
6.7
6.3
10.55
10.76
umol/l
0.13
121
989
86
660
1.49
2.15
3.1
3.2
77.67
159.75
e6/l
0.36
65
502
81
617
1.49
2.09
6.9
6.1
—
—
—
0
0
19
98
2.02
2.02
2.0
1.9
—
—
—
0
0
31
189
1.74
2.00
3.6
4.9
2.70
30.63
ug/l
0.68
24
157
168
1487
1.51
1.93
9.3
7.9
76.44
78.17
u/l
0.22
160
1410
106
866
1.42
1.85
5.3
5.8
1.21
1.21
mmol/l
0.55
99
804
70
531
1.46
1.81
2.8
2.1
2.33
2.80
mg/l
0.88
58
466
95
766
1.41
1.76
4.1
4.0
31.56
72.53
e6/l
1.52
69
529
6
19
3.21
1.67
2.2
1.3
—
—
—
0
0
5
14
3.63
1.62
3.4
4.6
548.20
710.86
mg
—
5
14
8
33
2.48
1.55
2.0
1.5
—
—
—
0
0
7
28
2.55
1.46
1.1
1.2
—
—
—
0
0
12
59
2.09
1.46
1.3
1.2
—
—
—
0
0
74
588
1.38
1.45
1.9
1.7
19.01
20.86
nmol/l
0.49
60
501
6
23
2.65
1.37
2.7
1.8
—
—
—
0
0
6
23
2.65
1.37
1.0
1.0
—
—
—
0
0
24
154
1.62
1.32
2.7
4.2
7.36
7.37
ph
0.23
15
108
9
44
2.09
1.28
1.1
1.1
—
—
—
0
0
9
44
2.09
1.28
1.1
1.1
—
—
—
0
0
38
274
1.47
1.26
1.8
1.9
—
—
—
0
0
124
1084
1.32
1.25
3.5
3.8
0.00
0.00
estimate
-0.00
18
237
6
25
2.44
1.25
1.8
2.0
—
—
—
0
0
21
133
1.64
1.22
1.2
1.3
—
—
—
0
0
75
613
1.33
1.21
2.7
2.5
56.33
64.66
u/l
0.46
67
581
6
26
2.34
1.19
1.3
1.4
—
—
—
0
0
190
1778
1.43
1.16
6.6
5.8
37.96
38.56
mmol/mol
0.50
179
1682
18
111
1.68
1.16
1.1
1.1
—
—
—
0
0
81
674
1.31
1.14
6.3
5.5
—
—
—
0
0
64
517
1.33
1.11
3.5
4.0
—
—
—
0
0
5
21
2.41
1.09
1.4
1.0
—
—
—
0
0
36
265
1.43
1.09
1.4
1.3
—
—
—
0
0
124
1098
1.29
1.08
3.6
3.8
0.00
0.00
estimate
-0.00
18
239
7
34
2.09
1.04
1.1
1.1
—
—
—
0
0
124
1102
1.28
1.03
3.6
3.8
0.00
1.35
estimate
0.50
18
224
11
61
1.84
1.00
1.7
2.9
—
—
—
0
0
6
118
0.50
0.97
1.2
1.1
—
—
—
0
0
199
1892
1.43
0.96
5.1
4.8
4.70
4.66
mmol/l
0.26
187
1779
207
1983
1.52
0.96
13.4
13.2
—
—
—
0
0
201
1915
1.45
0.96
5.9
5.4
2.77
2.72
mmol/l
0.30
187
1794
70
584
1.29
0.95
4.1
3.9
3.70
11.39
mg/mmol
2.36
41
369
6
27
2.25
0.94
1.2
1.3
—
—
—
0
0
6
28
2.17
0.92
1.3
1.2
—
—
—
0
0
13
79
1.68
0.90
1.4
1.5
1.42
1.32
mm
—
7
60
30
222
1.41
0.89
1.7
1.6
—
—
—
0
0
16
104
1.58
0.87
2.8
4.4
—
—
—
0
0
13
80
1.66
0.86
1.4
1.5
—
—
—
0
0
130
1178
1.24
0.86
10.2
9.4
4.35
4.08
e9/l
0.66
108
1013
69
582
1.27
0.86
3.7
3.3
27.49
66.96
mg/l
1.87
40
387
73
621
1.26
0.84
3.1
2.7
—
—
—
0
0
24
173
1.43
0.83
1.7
1.4
—
—
—
0
0
11
66
1.70
0.80
1.2
1.3
—
—
—
0
0
210
2028
1.50
0.80
13.4
11.4
22.21
24.41
u/l
2.61
204
1978
13
82
1.62
0.80
1.4
1.6
—
—
—
0
0
17
115
1.52
0.79
2.7
2.1
18746.59
5372.43
u/l
—
9
40
93
819
1.23
0.78
13.3
11.5
1.19
1.20
inr
0.01
76
669
99
878
1.23
0.78
3.4
3.4
6.31
6.18
ph
0.56
59
497
75
647
1.24
0.76
3.5
3.1
7.74
7.86
mmol/l
0.07
61
555
5
24
2.11
0.75
1.8
1.5
—
—
—
0
0
39
311
1.31
0.74
1.5
1.6
1069.89
1138.11
nmol/l
0.22
29
241
55
459
1.26
0.74
6.2
5.9
1.76
3.00
ug/l
0.96
47
399
7
38
1.87
0.74
2.7
3.2
3.07
6.44
umol/l
—
7
27
5
25
2.02
0.73
1.0
1.0
—
—
—
0
0
31
241
1.33
0.71
4.4
5.3
1.05
1.08
mmol/l
0.12
26
219
7
41
1.73
0.70
1.0
1.4
—
—
—
0
0
5
27
1.87
0.69
6.8
3.2
5.60
3.08
nmol/l
—
5
27
23
172
1.38
0.67
1.5
1.6
952.37
933.91
mu/l
0.02
16
148
106
958
1.20
0.67
2.6
2.8
—
—
estimate
—
0
0
146
1362
1.20
0.64
3.3
3.2
38.54
41.15
u/l
0.24
136
1301
35
283
1.28
0.61
3.1
2.5
79.29
118.46
ug/g
0.78
28
232
117
1073
1.19
0.61
3.8
3.1
78.61
96.19
ug/l
0.73
111
1016
196
1887
1.29
0.61
5.1
4.7
1.49
1.51
mmol/l
0.25
182
1766
71
623
1.20
0.60
2.6
3.1
0.00
0.14
estimate
0.52
16
188
7
112
0.61
0.60
2.9
2.8
1.19
1.29
%
—
7
112
7
111
0.62
0.60
2.9
2.8
0.67
0.61
%
—
7
111
165
1564
1.20
0.57
4.4
4.5
14.45
14.65
pmol/l
0.48
151
1436
27
213
1.30
0.57
6.9
7.2
1.44
0.64
mmol/l
0.43
20
180
117
1078
1.18
0.57
6.8
6.0
2.04
1.90
e9/l
0.59
99
955
108
991
1.17
0.54
7.1
5.9
29.91
27.98
%
1.17
101
943
9
61
1.49
0.54
1.2
1.1
—
—
—
0
0
13
91
1.45
0.54
1.3
1.9
—
—
—
0
0
46
392
1.22
0.53
2.9
2.5
2.44
2.44
mmol/l
0.07
40
355
27
216
1.28
0.52
7.0
7.2
7.39
7.42
ph
0.62
16
122
53
460
1.20
0.51
3.6
1.7
1.51
1.25
mg/l
0.15
42
355
122
1136
1.16
0.50
5.4
4.6
6.59
6.43
mmol/l
0.43
111
1056
12
165
0.71
0.48
7.1
4.9
0.20
0.90
%
—
5
54
56
491
1.19
0.48
3.9
3.7
—
0.00
—
0
5
11
153
0.70
0.47
7.5
4.9
0.00
0.59
%
—
5
44
190
1836
1.22
0.47
5.5
4.7
5.86
5.79
mmol/l
0.37
175
1700
73
656
1.17
0.47
2.2
2.3
—
—
—
0
0
106
981
1.15
0.46
6.9
5.8
55.47
57.41
%
1.09
99
933
113
1051
1.15
0.46
6.9
6.0
0.58
0.57
e9/l
0.24
94
899
71
784
0.86
0.44
2.5
2.9
—
—
—
0
0
185
1788
1.19
0.42
4.4
4.0
1.29
1.22
mmol/l
0.83
169
1651
0
16
0.00
0.41
0.0
1.6
—
7.79
—
0
16
0
16
0.00
0.41
0.0
1.1
—
287.10
—
0
10
90
829
1.14
0.41
3.2
3.6
0.00
0.02
estimate
0.74
16
196
13
171
0.75
0.41
4.2
3.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
29
243
1.22
0.40
1.6
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
32
272
1.21
0.39
2.2
1.6
—
—
—
0
0
9
67
1.36
0.38
2.4
2.8
1.22
1.44
mg/l
—
9
56
35
301
1.19
0.38
1.4
1.5
480.00
514.05
titre
—
5
74
12
157
0.75
0.37
7.1
5.1
0.00
0.16
%
—
5
45
11
81
1.38
0.37
2.6
3.2
—
—
—
0
0
5
78
0.63
0.36
1.0
1.1
—
0.49
—
0
7
5
78
0.63
0.36
1.0
1.1
1.54
1.60
g/l
—
5
78
104
974
1.13
0.36
7.2
5.9
8.68
8.66
%
0.02
96
916
112
1054
1.12
0.35
6.9
6.0
0.04
0.04
e9/l
0.01
93
898
6
43
1.41
0.35
4.8
2.8
55.83
62.95
%
—
6
43
116
1095
1.12
0.35
8.3
6.2
0.19
0.18
e9/l
0.27
102
953
15
118
1.29
0.34
3.3
2.1
—
—
—
0
0
46
412
1.15
0.31
2.0
1.7
—
—
—
0
0
103
971
1.11
0.31
7.3
5.9
2.97
2.73
%
0.52
95
911
189
1843
1.16
0.30
5.8
5.4
1.97
1.83
mu/l
0.40
173
1714
11
84
1.33
0.30
1.4
1.3
—
—
—
0
0
19
158
1.22
0.29
2.2
2.0
10.04
10.13
g/l
0.04
19
149
58
531
1.12
0.29
1.2
1.3
0.67
1.70
u/ml
—
7
151
8
63
1.28
0.28
1.4
1.1
—
—
—
0
0
29
253
1.17
0.28
2.4
3.2
3.97
5.06
e9/l
0.47
24
227
13
160
0.80
0.27
1.9
2.7
0.18
0.14
e6/l
0.17
13
154
102
968
1.10
0.26
7.4
5.9
0.68
0.65
%
0.34
92
902
11
87
1.28
0.25
1.2
1.5
252.82
280.02
mu/l
0.38
11
79
6
82
0.72
0.24
1.0
1.2
0.82
0.87
g/l
—
6
82
7
95
0.73
0.22
2.6
3.8
1.02
1.02
ratio
—
7
88
14
116
1.22
0.22
1.1
1.2
—
—
—
0
0
25
282
0.87
0.22
1.2
1.6
—
—
—
0
0
22
192
1.16
0.21
1.2
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.9
—
47.00
—
0
5
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
0.00
—
0
11
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
1861.70
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
27
241
1.14
0.20
1.4
1.4
—
—
—
0
0
6
52
1.16
0.19
2.0
1.9
—
—
—
0
0
17
147
1.17
0.18
1.4
1.2
191.24
260.56
u/ml
0.20
17
133
40
433
0.91
0.18
1.3
1.3
22.25
31.67
iu/ml
0.43
11
130
18
205
0.87
0.18
3.6
3.9
7.38
7.38
ph
—
10
119
7
61
1.15
0.17
1.0
1.2
15.17
11.74
u/l
—
7
42
73
694
1.08
0.17
3.9
2.9
2.35
2.35
mmol/l
0.14
62
633
15
172
0.86
0.16
1.6
2.0
5.75
6.16
ph
—
8
107
40
373
1.09
0.15
1.5
1.7
405.74
450.78
pmol/l
0.60
31
323
96
927
1.06
0.14
9.8
10.9
0.00
0.00
e9/l
0.53
76
742
51
485
1.07
0.12
3.6
3.5
1.02
1.02
kg/l
0.78
36
310
5
44
1.14
0.10
1.4
1.5
0.29
0.29
nmol/l
—
5
31
5
46
1.09
0.09
2.6
5.5
—
—
—
0
0
69
713
0.95
0.09
2.8
4.1
19.15
30.52
ng/l
1.20
41
465
11
98
1.13
0.08
1.2
1.4
—
—
—
0
0
8
90
0.88
0.07
1.9
1.8
1.13
1.56
g/l
—
8
81
61
595
1.03
0.05
3.2
3.7
0.00
0.00
estimate
-0.00
19
221
11
119
0.92
0.04
3.1
2.1
13.25
13.06
nmol/l
0.02
11
110
39
401
0.97
0.03
1.3
1.3
6.61
7.69
u/ml
0.07
15
155
47
480
0.97
0.02
4.4
5.0
—
—
—
0
0
18
172
1.05
0.02
1.5
1.8
3.49
3.32
mmol/l
0.28
11
126
19
182
1.05
0.02
9.8
7.8
—
—
—
0
0
50
492
1.02
0.01
1.5
1.4
2.76
2.28
g/l
0.66
27
287
18
173
1.04
0.01
1.3
1.3
105.33
139.69
u/ml
—
6
77
63
623
1.02
0.01
1.8
1.6
—
—
—
0
0
11
108
1.02
0.00
1.2
1.4
—
—
—
0
0
13
132
0.98
0.00
1.8
1.8
—
—
—
0
0
50
499
1.00
0.00
2.5
2.1
—
—
—
0
0
81
811
1.00
0.00
2.0
1.9
1.20
1.33
mmol/l
1.21
69
708
21
207
1.02
0.00
1.9
1.5
—
—
—
0
0
11
106
1.04
0.00
1.2
1.4
—
—
—
0
0
16
165
0.97
0.00
2.1
2.6
78.92
69.63
e9/l
—
10
128
19
195
0.97
0.00
3.6
4.0
3.30
1.51
mmol/l
1.62
14
162
27
272
0.99
0.00
3.4
3.3
0.66
0.79
ug/l
0.39
18
188
30
298
1.01
0.00
1.7
1.9
—
—
—
0
0
11
105
1.05
0.00
1.2
1.4
—
—
—
0
0
11
105
1.05
0.00
1.2
1.4
—
—
—
0
0
26
262
0.99
0.00
7.8
6.5
104.54
104.55
mmol/l
0.00
26
262
0
9
0.00
0.00
0.0
4.9
—
53.22
—
0
9
0
9
0.00
0.00
0.0
1.6
—
58.78
—
0
9
0
6
0.00
0.00
0.0
1.0
—
37.88
—
0
6
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
99.33
—
0
9
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
9.80
—
0
6
0
6
0.00
0.00
0.0
1.0
—
17.87
—
0
6
5
55
0.91
-0.00
2.0
1.2
—
121.67
—
0
6
6
61
0.98
-0.00
3.8
1.9
147.28
268.45
ug/l
—
6
56
0
5
0.00
-0.00
0.0
2.0
—
76.40
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
34.60
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
1.19
—
0
5
0
5
0.00
-0.00
0.0
2.4
—
0.52
—
0
5
0
8
0.00
-0.00
0.0
2.6
—
4.53
—
0
8
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
6
65
0.92
-0.00
1.2
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_MELANOCYTIC_EAR and mortality.

Females

Parameter HR [95% CI] p-value
CD2_BENIGN_MELANOCYTIC_EAR 1.145 [0.83, 1.59] 0.414
Birth year 0.995 [0.99, 1.0] 0.269

During the follow-up period (1.1.1998 — 31.12.2019), 58 out of 636 females with CD2_BENIGN_MELANOCYTIC_EAR died.

Males

Parameter HR [95% CI] p-value
CD2_BENIGN_MELANOCYTIC_EAR 1.019 [0.75, 1.38] 0.902
Birth year 0.986 [0.98, 1.0] 0.004

During the follow-up period (1.1.1998 — 31.12.2019), 79 out of 390 males with CD2_BENIGN_MELANOCYTIC_EAR died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_MELANOCYTIC_EAR.

N-year risk Females Males
1 0.13% 0.203%
5 0.676% 1.113%
10 1.628% 2.915%
15 3.122% 5.533%
20 5.382% 9.116%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_MELANOCYTIC_EAR – Melanocytic naevi of ear and external auricular canal

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data